PHASE 1 EVALUATION OF DIANHYDROGALACTITOL (NSC-132313)

  • 1 January 1976
    • journal article
    • research article
    • Vol. 60  (5) , 611-614
Abstract
A toxicologic evaluation of the antitumor drug dianhydrogalactitol in man was completed for a 5- and a 10-day schedule. The maximum tolerated dose was 30 mg/m2 per day for the 5-day schedule and 21 mg/m2 per day for the 10-day schedule. Dose-limiting myelosuppression occurred with both schedules, with leukopenia and thrombocytopenia being observed at median days 15 and 19, respectively, for the 5-day course and median days 22 and 26 for the 10-day course. Nausea was infrequent and mild. Responses were obtained in 1 patient with laryngeal carcinoma and in 1 patient with adenocarcinoma of the lung.